by According to the industry experts, The continuous glucose monitoring device market size is projected to reach around US$ 10.34 billion by 2030 from USD 4.7 billion in 2021 growing at a CAGR of 9.2% from 2021 to 2030. The report contains 150+ pages with detailed analysis.
The increasing awareness regarding the diabetes coupled with the growing prevalence of diabetes among the population is driving the growth of the continuous blood glucose monitoring device market. According to the International Diabetes Federation, around 700 million people will have diabetes around the globe, by 2045. The alarming rise in the number of overweight and obese people across the globe is expected to fuel the demand for the CGM device, as obesity and overweight are the major causes of diabetes.
The base year for the study has been considered 2021, the historic year 2019 and 2020, the forecast period considered is from 2021 to 2030. The continuous glucose monitoring device market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).
Download the Sample Pages of this Report for Better Understanding (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1374
Continuous Glucose Monitoring (CGM) Device Market Scope
This market report studies market dynamics, status and outlook especially in North America, Europe and Asia-Pacific, Latin America, the Middle East and Africa. This research report offers scenario and forecast (revenue/volume), and categorizes the market by key players and various segment. This report also studies global market prominence, competitive landscape, market share, growth rates market dynamics such as drivers, restraints and opportunities, and distributors and sales channels.
This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers a competitive scenario that comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.
According to the World Health Organization, more than 1.9 billion global population were overweight, out of which around 650 million adults were obese in 2016. The unhealthy food habits, lack of proper diet, busy and hectic schedules of the people, and lack of physical activities are the major contributors of the growing diabetic population. Moreover, the rising geriatric population is also a significant factor that contributes to the growth of the CGM device market. Old age population is prone to high blood glucose levels and diabetes.
Coverage of the Continuous Blood Glucose Monitoring Device Market
| Report Coverage | Details |
| Market Size in 2021 | USD 4.7 Billion |
| Growth Rate From 2021 to 2030 | CAGR of 9.2% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Base Year | 2021 |
North America dominated the global CGM device market, accounting for around 40% of the market share in 2020. North America is characterized by growing geriatric population, increased prevalence of diabetes, increased awareness regarding the CGM devices, increased consumer spending on the healthcare, and higher disposable income. All these factors positively contributes towards the growth of the CGM device market in the region. Furthermore, the presence of several prominent market players and various developmental strategies adopted by them has high influence on the market and the rising research and developmental activities adopted by them are expected to positively drive the market growth.
On the other hand, Asia Pacific is estimated to be the most opportunistic market during the forecast period. Asia Pacific is home to the huge population, characterized by rising awareness regarding diabetes, increasing awareness regarding the availability of CGM devices, and rising consumer expenditure on healthcare. Moreover, the rising penetration of diagnostic labs in the region is expected to augment demand for the CGM device during the forecast period. Countries like China, India, South Korea, and Indonesia are attracting FDIs in the healthcare sector owing to the favorable government policies, which is expected to dr4ive the growth of the CGM device market in the region.
Increased investments in the marketing of the CGM devices by the prominent market players significantly driven the demand for the CGM device among the population. The technological advancements in the CGM device like the introduction of improved sensors is further fueling the market demand across the globe.
The lack of awareness regarding the diabetes, increased illiteracy rate, and low income in the developing and the underdeveloped economies are the major restraining factors that may hinder the market growth in the forthcoming years.
The rising penetration of clinics, and diagnostic laboratories is expected to foster the demand for the CGM device in the forthcoming future. The rising disposable income and growing health consciousness will play a crucial role in the development of the CGM device market.
Based on the component, the sensors segment dominated the market, accounting for around 40% of the market share. The rapid adoption and extensive usage of sensor in the CGM has augmented the demand for the sensors across the globe. The sensors are considered accurate and effective in analyzing the blood glucose levels and hence its demand is high. With the advancements in the technologies, the efficiency of the sensors increased along with the increased affordability. The rising affordability will propel the demand for the CGM devices in the low and middle income countries.
Based on the end user, the home healthcare segment garnered a market share of around 42%, leading the global market. The easy availability of numerous CGM devices across the globe has fostered the growth of this segment. Further, the increased prevalence of diabetes and rising awareness among the population regarding the diabetes control and preventive measures has significantly contributed towards the growth of this segment.
Read Article – Medical Supplies Market Size to Reach US$ 181.06 Billion By 2030
Continuous Glucose Monitoring Device Key Players/Manufacturers
This report also provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the continuous glucose monitoring device market and ranks noticeable companies as per their occurrence in diverse regions across the globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.
Some of the prominent players in the global continuous glucose monitoring device market include:
- Abbott Laboratories
- Dexcom, Inc.
- A. Menarini Diagnostics
- Echo Therapeutics, Inc.
- GlySens Incorporated
- Johnson & Johnson
- Medtronic plc
- Senseonics Holdings, Inc.
- F. Hoffmann-La Roche Ltd
- Ypsomed
Continuous Glucose Monitoring Device Market Segments Covered
By Component
- Transmitters
- Receivers
- Sensors
- Integrated Insulin Pumps
By End User
- Hospitals
- Home Healthcare
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of the World
Research Objective
- To provide a comprehensive analysis of the continuous glucose monitoring device industry and its sub-segments in the global market, thereby providing a detailed structure of the industry
- To provide detailed insights into factors driving and restraining the growth of this global market
- To provide a distribution chain analysis/value chain for the this market
- To estimate the market size of the global continuous glucose monitoring device market where 2019 would be the historical period, 2020 shall be the base year, and 2020 to 2027 will be the forecast period for the study
- To provide strategic profiling of key companies (manufacturers and distributors) present across the globe, and comprehensively analyze their competitiveness/competitive landscape in this market
- To analyze the global market in four main geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World
- To provide country-wise market value analysis for various segments of the continuous glucose monitoring device
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Continuous Glucose Monitoring (CGM) Device Market
5.1. COVID-19 Landscape: Continuous Glucose Monitoring (CGM) Device Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Continuous Glucose Monitoring (CGM) Device Market, By Component
8.1. Continuous Glucose Monitoring (CGM) Device Market, by Component Type, 2021-2030
8.1.1. Transmitters
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Receivers
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Sensors
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Integrated Insulin Pumps
8.1.4.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Continuous Glucose Monitoring (CGM) Device Market, By End User
9.1. Continuous Glucose Monitoring (CGM) Device Market, by End User, 2021-2030
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Home Healthcare
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Others
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Continuous Glucose Monitoring (CGM) Device Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Component (2019-2030)
10.1.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Component (2019-2030)
10.1.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Component (2019-2030)
10.1.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Component (2019-2030)
10.2.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Component (2019-2030)
10.2.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Component (2019-2030)
10.2.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Component (2019-2030)
10.2.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Component (2019-2030)
10.2.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Component (2019-2030)
10.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Component (2019-2030)
10.3.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Component (2019-2030)
10.3.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Component (2019-2030)
10.3.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Component (2019-2030)
10.3.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Component (2019-2030)
10.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Component (2019-2030)
10.4.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Component (2019-2030)
10.4.4.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Component (2019-2030)
10.4.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Component (2019-2030)
10.4.6.2. Market Revenue and Forecast, by End User (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Component (2019-2030)
10.5.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Component (2019-2030)
10.5.3.2. Market Revenue and Forecast, by End User (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Component (2019-2030)
10.5.4.2. Market Revenue and Forecast, by End User (2019-2030)
Chapter 11. Company Profiles
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Dexcom, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. A. Menarini Diagnostics
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Echo Therapeutics, Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. GlySens Incorporated
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Johnson & Johnson
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Medtronic plc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Senseonics Holdings, Inc.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. F. Hoffmann-La Roche Ltd
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Ypsomed
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Why Buy this Report?
The purpose of Precedence Research’s continuous glucose monitoring device market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.
Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1374
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
